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Abstract
We describe a case of cerebral schistosomiasis, caused by Asian (oriental) Schistosoma japonicum trematode blood
flukes, in a young Chinese patient and its management. We also provide a brief update for physicians on the
clinical features, diagnosis and treatment of schistosomiasis, with particular emphasis on neuroschistosomiasis, the
most severe clinical outcome associated with this parasitic infection.
Background
Although not commonly reported in western countries,
schistosomiasis is, after malaria, the second most preva-
lent tropical disease, affecting over 200 million people
[1]. It is an intravascular disease, caused by dioecious
parasitic trematode worms of the genus Schistosoma.
Eggs released by adult female worms cause the majority
of lesions in schistosomiasis when they embolize in the
liver, spleen, lungs, or urino-genital or cerebrospinal sys-
tems [1-3]. Egg secretions provoke eosinophilic inflam-
matory and granulomatous reactions which are
progressively replaced by fibrotic deposits [1,2]. Schisto-
somiasis is thus associated with chronic liver and intest-
inal or genitourinary tract fibrosis. Neurological
complications can also develop, and neuroschistosomia-
sis is the most severe clinical outcome associated with
schistosome infection [1,2]. Neurological complications
during the early course of infection are thought to occur
through in situ egg deposition following aberrant migra-
tion of adult worms to the brain or spinal cord [1,2].
The presence of eggs in the central nervous system
(CNS) induces a Th2 driven periovular granuloma reac-
tion [1]. The mass effect of thousands of eggs and the
large granulomas concentrated within the brain or
spinal cord explain the signs and symptoms of increased
intracranial pressure, focal neuropathy and subsequent
clinical sequel associated with neuroschistosomiasis [1].
The Asian schistosome species (S. japonicum;
S. mekongi) lay up to 3000 eggs daily with the resulting
morbidity being more severe than with the African
forms (S. mansoni; S. haematobium; S. intercalatum),
which produce ten times fewer eggs per day [1,2]. Mye-
lopathy (acute transverse myelitis and subacute myelora-
diculopathy) of the lumbosacral region is the most
common neurological manifestation of S. mansoni or
S. haematobium infection, whereas acute encephalopha-
litis of the cortex, subcortex, basal ganglia or internal
capsule is typical of S. japonicum [1,2].
Only a minority (<5%) of patients will develop CNS
symptoms due to schistosomiasis, with cerebral compli-
cations being more prevalent than spinal [1]. Cerebral
complications include: headache, visual impairment,
delirium, seizures, motor deficits and ataxia, whereas,
spinal symptoms comprise: lumbar pain, lower limb
radicular pain, muscle weakness, sensory loss and blad-
der dysfunction [1,2]. The onset of neurological symp-
toms usually takes place within weeks to months, and
progress in an acute or subacute manner with the symp-
toms and signs of the disease worsening over time [1,2].
We describe the diagnosis of a young Chinese schisto-
somiasis patient with cerebral involvement and its suc-
cessful management, and briefly review the clinical
features, diagnosis and treatment of the disease.
Case presentation
A 14-year-old female presented to Xiang-Yue hospital,
Yueyang City, Hunan Province, People’s Republic of
China with a four month history of vertigo, headache,
vomiting and syncope. The patient had lived in the
Dongting Lake region, a highly endemic area for
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schistosomiasis, since birth. The patient reported no
past medical history of epilepsy, tuberculosis, hepatitis
B/C and no known drug allergies. Upon physical exami-
nation, the patient’s vital signs were within normal lim-
its; she had no evidence of skin itching, no fever, no
bloody stool, no obvious abdominal discomfort was
observed and no other neurological signs were detected.
Electrocardiography and chest X-ray were unremarkable.
Hematological testing revealed evidence of eosinophilia
(eosinophil count 0.8 × 109) but white blood cells (white
blood cell count, 5.6 × 109; lymphocyte count 1.2 × 109;
neutrophil count 3.4 × 109), liver and renal functions
were within normal limits. Serological tests were positive
for S. japonicum infection both by indirect haemaggluti-
nation and enzyme linked immunosorbent assays, using
soluble egg antigen. S. japonicum eggs were further
detected in the stool by Kato-Katz thick smear stool
examination confirming the diagnosis. Ultrasound exam-
ination showed a wide echo dot pattern and increased
echogenicity but no network in the liver (Figure 1A),
and no abnormality in the size or texture of the spleen
(Figure 1B). An unenhanced axial section computed
tomography (CT) brain scan showed a 1.6 × 2.4 cm iso-
density mass in the left parietal lobe with edema (Figure
2A1). Axial section magnetic resonance imaging (MRI)
showed two hypointensity and hyperintensity lesions on
T1- (Figure 2B1) and on T2-weighted spin-echo images
(Figure 2C1), respectively. Multiple small nodular or
‘silt-like’ enhancements clustered in the sub-cortical
region were evident following intravenous administra-
tion of Gadolinium-DTPA (Figure 2D1). A diagnosis of
‘cerebral schistosomiasis’ was subsequently made and
the patient was treated intravenously with 20% mannitol
(125 ml daily for 5 days) to lower the intracranial pres-
sure and orally with praziquantel (PZQ) (120 mg/kg
three times a day for six days after meal). Follow-up
MRI and CT scans (25 days post PZQ treatment)
showed that the edema and lesions were partially
resolved and were almost completely resolved 3 months
post PZQ (Figure 2D3).
Conclusions
Schistosome infection can provoke an urticarial rash
that often persists for days as a maculopapular lesion
[4]. Katayama syndrome (acute schistosomiasis) is a sys-
temic hypersensitivity reaction against the migrating
parasite or its eggs [1,4]. In many cases, acute infections
are asymptomatic. Symptoms that manifest result from
an allergic reaction during larval migration and early
oviposition by adult worms [4]. Disease onset is usually
sudden, producing many non-specific symptoms, such
as fever, fatigue, myalgia, malaise, urticaria, non-produc-
tive cough, eosinophilia, and patchy pulmonary infil-
trates on chest radiograph [1,5]. Abdominal symptoms
Figure 1 Ultrasound examination of the patient’s liver (A) and spleen (B).
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Figure 2 Unenhanced axial section CT scan of the patient’s brain (A). A 1.6 × 2.4 cm isodensity mass (black arrows) in the left parietal lobe
with edema (white arrows) surrounding (A1) prior to praziquantel (PZQ)-treatment. Marked decrease in the size of the mass (black arrows) and
reduced edema (white arrows) were evident 21 days post-PZQ treatment (A2). Axial section MRI of the patient’s brain (B,C). Hypointensity lesions
(white arrows) on T1-weighted spin-echo images pre-PZQ treatment (B1) were almost absolved at 25 days post-PZQ treatment (B2) and
absorbed at 3 months post-PZQ treatment (B3). Hyperintensity lesions on T2-weighted spin-echo images prior to treatment with PZQ (white
arrows) (C1) were decreased in size 25 days post-PZQ treatment (white arrows) (C2) and were almost totally resolved at 3 months post-PZQ
treatment (C3). Enhanced MRI of the patient’s brain (D). Multiple small nodules (white arrows) scattered or clustered at the cortical/subcortical
area following intravenous administration of gadolinium-DTPA pre-PZQ treatment (D1) and two nodular enhancements (white arrows) observed
at 25 days post-PZQ treatment (D2); almost all nodules were absolved at 3 months post-PZQ treatment (D3).
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may develop within a few weeks, because of migration
of juvenile worms and egg deposition of the mature
worms [5]. High-grade nocturnal fever and eosinophilia
are generally present [5]. Most patients recover sponta-
neously after 2-10 weeks, whereas some develop persis-
tent and more serious disease with weight loss,
dyspnoea, diarrhoea, diffuse abdominal pain, hepatome-
galy, and generalized rash [4].
Neurological disease resulting from schistosome infec-
tion is thought to occur through egg embolism or aber-
rant migration of adult worms to the brain or spinal
cord [6,7]. Central nervous system (CNS) involvement
has been described in soldiers and aid workers serving
in areas where schistosomiasis is endemic [6-8], and in
tourists who have had relatively limited exposure to
such areas or the parasite [1]. Focal or generalized
tonic-clonic epilepsy is a typical presentation for S. japo-
nicum infection with CNS involvement [1]. Focal neuro-
logic deficits may also occur. Among groups of Chinese
adults hospitalized with schistosomiasis, up to 4.3%
were shown to have CNS disease [9]. The prevalence of
epilepsy in communities where infections have occurred
has been estimated at 1-4% which is eight times higher
than that of the general population [9,10].
Routine screening of patients following freshwater
exposure to schistosomiasis should consist of a full
blood count, absolute eosinophil count, serology (parti-
cularly the presence of IgE antibodies), and faecal
microscopy. The detection of schistosome eggs in urine
or in faeces by the rapid, simple and inexpensive Kato-
Katz thick-smear stool examination is diagnostic [1,2].
Commercially available immunodiagnostic kits are gen-
erally not as sensitive as multiple faecal examinations
and are less specific, due to cross-reactivity with other
helminths. Most techniques detect IgG, IgM or IgE
against soluble worm antigen or crude egg antigen by
ELISA, indirect hemagglutination or immunofluores-
cence [1,2].
Praziquantel is the foremost-prescribed drug and is
highly effective against the adult worms of all Schisto-
soma species. It is usually augmented by a course of
corticosteroids and anticonvulsants in patients present-
ing with neurological complications [1,3]. A derivative
of the antimalarial drug, artemisinin (artemether), has
been shown effective against young schistosome para-
sites [11].
Schistosomiasis is potentially a public health risk to
those travelling to endemic areas within Africa and Asia
who may be accidentally exposed to infection though
contact with cercariae in freshwater canals, lakes, rivers,
or springs. Schistosomiasis is not a notifiable disease in
many developed countries, including the USA, so there
is no accurate information about infection rates among
returned travelers and immigrants [1]. Patients can pre-
sent with neurological complications. When sympto-
matic, neuroschistosomiasis (NS) is the most severe
presentation of schistosome infection; cerebral invasion
is mostly caused by S. japonicum, with spinal cord invol-
vement due mainly to S. mansoni or S. haematobium
[7]. The chief neurological feature is diffuse encephalo-
pathy and seizures [12,13]. Patients typically present
with any of the following symptoms: headache, papille-
dema, nystagmus, speech disturbances, some degree of
motor weakness (hemiplegia, paraplegia or quadriplegia),
and cranial nerve abnormalities due to the formation of
mass granulomatous lesions and increased intracranial
pressure in the cortex, subcortex, basal ganglia or inter-
nal capsule [12,13]. Focal or generalized tonic-clonic
epilepsy is a typical presentation for S. japonicum infec-
tion with CNS involvement. Cerebral involvement due
to S. mansoni or S. haematobium typically involves the
cerebral and cerebellar cortex and leptomeninges, with
myelopathy, such as transverse myelitis, being the most
common neurologic manifestation [12,13]. Myleoradicu-
lopathy occurs far less frequently than the cerebral form
of the disease [12,13]. Patients with spinal schistosomia-
sis usually present with lumbar pain, lower limb radicu-
lar pain, muscle weakness, sensory loss and bladder
dysfunction due to egg deposition and granuloma for-
mation in the spinal cord or cauda equina. This is typi-
cally seen in S. mansoni and S. haematobium infections
but is less frequent in S. japonicum patients [12,14].
Spinal schistosomiasis can also present as a progressive
paraparesis mimicking a spinal cord neoplasm [12].
Cognitive impairment and memory loss deficits have
also been described among children infected with S.
japonicum and S. mansoni [15,16].
The true prevalence of neuroschistosomiasis is yet
unknown and is presently estimated at between 1-5% of
all diagnosed cases of schistosomiasis. There is also a
lack of clinical data regarding the timing of treatment,
results of surgery and combination therapy [12]. A com-
plete or partial recovery occurs in 70% of patients with
myeloradiculopathy [14], but a less favorable outcome is
seen for those treated for transverse myelitis. Earlier
diagnosis and prompt treatment should improve the
prognostic outlook.
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